Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Early and Low Dose Deferasirox (3.5 mg/kg FCT) to Suppress NTBI and LPI as Early Intervention to Prevent Tissue Iron Overload in Lower Risk MDS

NCT03920657 is registered in ClinicalTrials.gov with Fondazione Italiana Sindromi Mielodisplastiche-ETS as lead sponsor.

NCT NCT03920657
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03920657 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Early and Low Dose Deferasirox (3.5 mg/kg FCT) to Suppress NTBI and LPI as Early Intervention to Prevent Tissue Iron Overload in Lower Risk MDS
Lead sponsor
Fondazione Italiana Sindromi Mielodisplastiche-ETS
Phase
Phase 2
Overall status
Terminated
Start date
October 4, 2019
Completion date
April 22, 2022
Enrollment
11 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

myelodysplastic syndromes